Technical Analysis for OCUL - Ocular Therapeutix, Inc.

Grade Last Price % Change Price Change
grade B 7.07 2.17% 0.15
OCUL closed up 2.17 percent on Thursday, June 4, 2020, on 83 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical OCUL trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
MACD Bearish Signal Line Cross Bearish 2.17%
NR7 Range Contraction 2.17%
NR7-2 Range Contraction 2.17%
Inside Day Range Contraction 2.17%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Spinning Top Other -0.98%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Health Medical Specialties Pain Clinical Trial Glaucoma Cataract Treatment Of Glaucoma Eye Diseases Incisions Allergic Conjunctivitis Allergology Cataract Surgery Ocular Hypertension Post Surgical Ocular Inflammation

Is OCUL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.12
52 Week Low 2.46
Average Volume 878,013
200-Day Moving Average 4.59
50-Day Moving Average 5.88
20-Day Moving Average 6.71
10-Day Moving Average 6.93
Average True Range 0.58
ADX 30.11
+DI 25.00
-DI 15.30
Chandelier Exit (Long, 3 ATRs ) 5.88
Chandelier Exit (Short, 3 ATRs ) 7.60
Upper Bollinger Band 7.46
Lower Bollinger Band 5.95
Percent B (%b) 0.74
BandWidth 22.65
MACD Line 0.33
MACD Signal Line 0.34
MACD Histogram -0.0068
Fundamentals Value
Market Cap 205.42 Million
Num Shares 29.1 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -3.29
Price-to-Sales 88.04
Price-to-Book 3.48
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.69
Resistance 3 (R3) 7.65 7.41 7.58
Resistance 2 (R2) 7.41 7.25 7.43 7.55
Resistance 1 (R1) 7.24 7.16 7.33 7.28 7.51
Pivot Point 7.00 7.00 7.04 7.02 7.00
Support 1 (S1) 6.83 6.84 6.92 6.87 6.63
Support 2 (S2) 6.59 6.75 6.61 6.59
Support 3 (S3) 6.42 6.59 6.56
Support 4 (S4) 6.46